Novoeight (Turoctocog Alfa)

Turoctocog alfa is a recombinant form of human factor VIII that replaces the missing clotting protein in hemophilia A. By restoring factor VIII activity in the intrinsic coagulation pathway, it enables the generation of thrombin and formation of a stable fibrin clot, thereby correcting the bleeding tendency associated with the disorder.

The dose of Novoeight is individualized and determined by the prescribing clinician based on the patient’s weight, baseline factor VIII level, severity of bleeding, and the clinical situation (e.g., prophylaxis or surgery). The prescriber calculates the required units to achieve target factor VIII activity and adjusts subsequent dosing as needed.

Safety data for Turoctocog alfa in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or while breastfeeding should only be considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it must be prescribed by a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Novoeight. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Novoeight (turoctocog alfa) is a recombinant, full‑length factor VIII produced in a Chinese hamster ovary cell line, offering high purity and consistent activity. Compared with plasma‑derived products, it eliminates the risk of viral transmission and provides a predictable pharmacokinetic profile. Relative to other recombinant factor VIIIs, it has similar efficacy, with differences mainly in manufacturing processes and dosing intervals.

Novoeight must be stored refrigerated at 2‑8 °C (36‑46 °F). The vials should be kept in their original packaging to protect from light, must not be frozen, and should not be shaken vigorously. If the product has been inadvertently frozen or exposed to temperatures above 8 °C for an extended period, it should be discarded.

Novoeight is supplied as a sterile solution for injection and is administered intravenously. The infusion is performed by a healthcare professional using aseptic technique, typically through a peripheral or central venous line. The rate of infusion is guided by the product’s prescribing information and the patient’s clinical response.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor VIII, which can reduce efficacy, and rare hypersensitivity reactions such as anaphylaxis. Thrombotic events may also occur if factor VIII levels become excessively high. Patients should be monitored regularly for inhibitor formation and any signs of severe allergic response.

Novoeight is contraindicated in patients with known hypersensitivity to turoctocog alfa or any of the excipients in the formulation. It should also be avoided in individuals who have previously experienced severe allergic reactions, including anaphylaxis, to other recombinant factor VIII products. Use in such patients requires careful evaluation by a hemophilia specialist.